Table 4 Percentage changes from baseline of characteristics of abdominal obesity subjects after 3-year intervention

From: Prevention of metabolic disorders with telmisartan and indapamide in a Chinese population with high-normal blood pressure

 

Placebo group (n=153)

Telmisartan group (n=149)

Indapamide group (n=142)

P-value

WC (% change)

−1.1 (−2.4, 0.3)

−1.1 (−2.6, 0.4)

−1.1 (−2.6, 0.0)

0.718

SBP (% change)

−4.7 (−4.7, −1.6)

−11.7 (−14.3, −9.0)a

−11.2 (−14.1, −7.8)a

0.000

DBP (% change)

−4.3 (−4.3, −0.8)

−10.9 (−13.8, −4.7)a

−9.7 (−13.7, −4.7)a

0.000

TG (% change)

−0.0 (−12.1, 14.3)

−1.8 (−1.8, −13.4)

−1.3 (−17.6, 10.6)

0.911

HDL-C (% change)

2.7 (−7.0, 22.6)

6.5 (−8.5, 31.7)

2.4 (−9.4, 16.0)

0.217

LDL-C (% change)

−8.5 (−23.9, −1.1)

−12.3 (−24.6, 1.1)

−8.0 (−18.9, −0.1)

0.660

FPG (% change)

−3.3 (−9.3, 0.5)

−4.4 (−10.8, 0.6)

−3.1 (−7.8, 0.5)

0.058

  1. Abbreviations: DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglycerides; WC, waist circumference.
  2. Values are medians (25th, 75th percentiles).
  3. aP<0.05 vs. placebo group.
Back to article page